Article in Journal of chemical information and modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 6 institutions in 1 country.
Yazdan MaghsoudDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID 0000-0002-4051-0844
Erik Antonio Vázquez-MontelongoDepartment of Physical Medicine and Rehabilitation, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.ORCID 0000-0001-5253-7887
Xudong YangDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
Chengwen LiuDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0002-3930-7793
Zhifeng JingDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0001-7013-036X
Juhoon LeeDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States.
Matthew HargerDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
Ally K SmithDepartment of Chemistry, University of North Texas, Denton, Texas 76201, United States.
Miguel EspinozaDepartment of Chemistry, University of North Texas, Denton, Texas 76201, United States.
Hou-Fu GuoDepartment of Molecular and Cellular Biochemistry, College of Medicine, The University of Kentucky, Lexington, Kentucky 40536, United States.
Jonathan M KurieDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77005, United States.
Kevin N DalbyDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0001-9272-5129
Pengyu RenDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0002-5613-1910
G Andrés CisnerosDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID 0000-0001-6629-3430
The University of Texas at Austin · USThe University of Texas at Dallas · USUniversity of North Texas · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USUniversity of Kentucky · US
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Regulation of Lung Cancer Metastasis by a Procollagen Lysine HydroxylaseR01CA105155 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2004 to 2019
$4.0M
DEVELOPMENT OF A NEXT-GENERATION NUCLEIC ACID FORCE FIELDR01GM106137 · NIGMS · WASHINGTON UNIVERSITY · PI JAY PONDER, Pengyu Ren · 2013 to 2026
$3.5M
Theory and Simulation of DNA Repair Enzymes; Mechanism, Structure and FunctionR01GM108583 · NIGMS · WAYNE STATE UNIVERSITY · PI CISNEROS, GERARDO ANDRES · 2014 to 2022
$2.9M
Specificity and Selectivity in Protein-Ion BindingR01GM114237 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI PONDER, JAY, REN, PENGYU · 2015 to 2023
$2.6M
Computational Simulations of DNA Transaction Enzymes - Application and DevelopmentR35GM151951 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI Gerardo Andres Cisneros · 2024 to 2026
$1.2M
Determining structural features of a collagen lysyl hydroxylase that promotes lung cancer metastasisR00CA225633 · NCI · UNIVERSITY OF KENTUCKY · PI GUO, HOUFU · 2020 to 2022
The catalytic function of lysyl hydroxylase-2 (LH2), a member of the Fe(II)/αKG-dependent oxygenase superfamily, is to catalyze the hydroxylation of lysine to hydroxylysine in collagen, resulting in stable hydroxylysine aldehyde-derived collagen cross-links (HLCCs). Reports show that high amounts of LH2 lead to the accumulation of HLCCs, causing fibrosis and specific types of cancer metastasis. Some members of the Fe(II)/αKG-dependent family have also been reported to have intramolecular O
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Computational Investigation of a Series of Small Molecules as Potential Compounds for Lysyl Hydroxylase-2 (LH2) Inhibition. · full record | OpenQuestion